Salarius Pharmaceuticals, Inc.

SLRX A | $0.4848 -2.88% 6.2K

(0.0% 1d) (-15.0% 1m) (-69.3% 1y) (0.0% 2d) (0.0% 3d) (2.7% 7d) (407.22% volume)
Earnings Calendar: 2023-03-09
Market Cap: $ 2,091,637
http://salariuspharma.com/
Sec Filling | Patents | 8 employees

(US) Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The firm focuses on the development of Salarius’ clinical pipeline, which targets rare, orphan cancers and cancers with a high unmet need. The company was founded in 2014 and is headquartered in Houston, TX.

cancer ewing sarcoma

add to watch list Paper trade email alert is off

Press-releases

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-22 (Crawled : 20:00) - globenewswire.com
SLRX A | $0.4848 -2.88% 6.2K

Commercial Services

| Email alert Add to watchlist
business year update pharmaceuticals financial results

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
SLRX A | $0.4848 -2.88% 6.2K

Commercial Services

| -10.54% | O: -0.02% H: 7.98% C: -1.93%
review update ongoing seclidemstat trials

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
Published: 2024-01-16 (Crawled : 13:00) - globenewswire.com
SLRX A | $0.4848 -2.88% 6.2K

Commercial Services

| -16.39% | O: 1.48% H: 2.57% C: -3.72%
patent pharmaceuticals protein

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
Published: 2024-01-03 (Crawled : 13:30) - globenewswire.com
SLRX A | $0.4848 -2.88% 6.2K

Commercial Services

| -20.32% | O: 4.67% H: 4.4% C: -4.66%
treat seclidemstat trial

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
Published: 2023-11-07 (Crawled : 14:00) - globenewswire.com
SLRX A | $0.4848 -2.88% 6.2K

Commercial Services

| -36.25% | O: 11.25% H: 4.49% C: -6.85%
fda seclidemstat meeting program

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
Published: 2023-08-10 (Crawled : 20:00) - globenewswire.com
SLRX A | $0.4848 -2.88% 6.2K

Commercial Services

| -25.95% | O: -2.69% H: 5.49% C: -3.33%
business update pharmaceuticals financial results

Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources
Published: 2023-08-08 (Crawled : 20:00) - globenewswire.com
SLRX A | $0.4848 -2.88% 6.2K

Commercial Services

| -39.54% | O: -2.29% H: 0.0% C: -7.85%
pharmaceuticals

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
Published: 2023-07-11 (Crawled : 12:20) - globenewswire.com
SLRX A | $0.4848 -2.88% 6.2K

Commercial Services

| -64.83% | O: 3.45% H: 0.01% C: -15.33%
sp-3164 fda drug clearance pharmaceuticals application trial

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress
Published: 2023-06-12 (Crawled : 12:00) - globenewswire.com
SLRX A | $0.4848 -2.88% 6.2K

Commercial Services

| -69.09% | O: 6.06% H: 0.0% C: -5.71%
sp-3164 association pharmaceuticals preclinical protein

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Published: 2023-05-16 (Crawled : 20:00) - globenewswire.com
SLRX A | $0.4848 -2.88% 6.2K

Commercial Services

| -63.57% | O: 0.71% H: 2.13% C: 1.42%
nasdaq pharmaceuticals

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001615219-24-000034	4	2024-04-12	2024-04-11	Buy	A	20500	20500
0001615219-24-000013	4	2024-02-22	2024-02-20	Buy	A	20500	20500
0001615219-24-000011	4	2024-02-22	2024-02-20	Buy	A	20500	20500